Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02627742 · ClinicalTrials.gov registry record · NA
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
A NA study of Atelectasis and Pulmonary Complications, sponsored by Hill-Rom.
- Completed
- Registry status
- NA
- Development phase
- 419
- Enrollment target
- 3
- Study locations
NCT02627742: Completed NA study of Atelectasis and Pulmonary Complications, sponsored by Hill-Rom.
NCT02627742 is a NA study of Atelectasis and Pulmonary Complications that has completed, run by Hill-Rom. The registered enrollment target is 419 participants, above the 97-participant average among 3 other Atelectasis trials with a reported enrollment target (332% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02627742, a NA study of Atelectasis and Pulmonary Complications, has completed, sponsored by Hill-Rom.
- COMPLETED
- Registry status
- NA
- Development phase
- 419 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine if a therapy regimen including treatment with The MetaNeb® System had a positive impact on the rate of pulmonary complications related to atelectasis and/or secretion retention that occur in high risk post-operative patients. This is a non-randomized facility (or hospital) level pre-post intervention study.
Primary Outcome
One or more of the following that occurs within seven (7) days of the post-surgical admission will be considered a Significant Postoperative Pulmonary Complication (PPC) * Patient requires prolonged mechanical ventilation (\> 24 hours from post-surgical admission) * Patient requires prolonged respiratory support for \> 24 hours from post-surgical admission * Diagnosis of pneumonia within seven (7) days * Readmission to ICU for pulmonary complications within seven (7) days of post-surgical hospi
Conditions Studied
Interventions
- DEVICE MetaNeb® System
Study Locations (3)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
North Carolina
- Carolinas Medical Center - Charlotte
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-08 |
| Phase | NA |
What the finished NCT02627742 record still lists
NCT02627742 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, above the 97-participant average among 3 other Atelectasis trials with a reported enrollment target (332% higher).
The record links to 2 conditions, with Atelectasis appearing as the primary indexed condition, and to 1 intervention - of which MetaNeb® System is the first listed.
NCT02627742 reports a single indexed study location in Massachusetts, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02627742 about?
NCT02627742 is a clinical study titled "Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications". To determine if a therapy regimen including treatment with The MetaNeb® System had a positive impact on the rate of pulmonary complications related to atelectasis and/or secretion retention that occur in high risk post-operative patients. This is a non-randomized facility (or hospital) level pre-pos...
What is the current status of trial NCT02627742?
This trial is currently completed. It is a NA study. The enrollment target is 419 participants. The study started on 2016-03. Estimated completion is 2017-08.
What conditions does trial NCT02627742 study?
This clinical trial studies the following conditions: Atelectasis, Pulmonary Complications.
What interventions are being tested in trial NCT02627742?
The interventions under investigation include: MetaNeb® System (DEVICE).
Who is sponsoring clinical trial NCT02627742?
This trial is sponsored by Hill-Rom, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02627742 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atelectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia